# A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD)

> **NCT07591727** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Alzheimer s Disease

## Interventions

- **DRUG:** Gut-X-001 + Placebo capsule
- **DRUG:** Gut-X-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07591727
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591727, "A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07591727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*